GlassScriptPhysician profile
Joseph S Thomas
NPI 1437258506
$1,232.64
in general payments reported to CMS, 2019-2025
22 companies · $69.74 in 2025
The $69.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $239 · 2021: $209 · 2023: $20.27 · 2025: $69.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.22 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.22 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $247.10 | 2019-2021 | |
| Pfizer INC. | $239.56 | 2019-2020 | |
| Astellas Pharma US INC | $138.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $122.18 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $81.06 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $59.65 | 2019-2020 | |
| Novo Nordisk INC | $49.84 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.13 | 2019-2021 | |
| Almatica Pharma LLC | $36.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.93 | 2019-2020 | |
| Stryker Corporation | $27.35 | 2025 | Smartlock |
| Dexcom, INC. | $24.48 | 2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $19.48 | 2023 | Vraylar |
| Boston Scientific Corporation | $17.81 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.01 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $16.97 | 2019 | |
| Biogen, INC. | $16.18 | 2021 | |
| Evoke Pharma, INC. | $12.69 | 2021 | |
| Merck Sharp & Dohme LLC | $11.78 | 2019 | |
| Allergan, INC. | $11.26 | 2020 | |
| Eisai INC. | $10.99 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.